Hepatitis A, B, and C: Clinical Pharmacology, Management, and Exam Essentials

Hepatitis remains a global public health burden, with over 2 million new chronic HCV infections annually and 1.4 million deaths from liver disease worldwide. Clinicians routinely encounter patients with acute hepatitis A, chronic hepatitis B, or chronic hepatitis C, each requiring distinct therapeutic strategies and vigilant monitoring. In this article, we dissect the pharmacology of antiviral agents, highlight key safety considerations, and distill exam‑relevant pearls that will sharpen your clinical acumen and test performance.

Introduction and Background

The hepatitis viruses were first described in the early 20th century, with hepatitis A (HAV) identified as an enterically transmitted pathogen in the 1950s and hepatitis B (HBV) recognized as a blood‑borne virus in the 1960s. Hepatitis C (HCV) was isolated in the 1980s, revealing a highly heterogeneous RNA virus that has become the leading cause of chronic liver disease in the United States. Epidemiologically, HAV remains endemic in low‑income regions with poor sanitation, whereas HBV and HCV continue to circulate in high‑risk populations such as intravenous drug users and healthcare workers.

Pathophysiologically, HAV is a non‑enveloped, positive‑sense RNA virus that causes an acute, self‑limited infection. HBV is a partially double‑stranded DNA virus that integrates into hepatocyte genomes, leading to chronic infection, cirrhosis, and hepatocellular carcinoma. HCV, an enveloped, positive‑sense RNA virus, relies on a highly variable replication complex that evades host immunity, resulting in chronic disease. The host immune response—particularly T‑cell mediated cytotoxicity—plays a pivotal role in viral clearance for HAV and in the progression of liver injury for HBV and HCV.

Pharmacological intervention has evolved from interferon‑based regimens to nucleos(t)ide analogues and direct‑acting antivirals (DAAs). For HBV, reverse‑transcriptase inhibitors such as tenofovir and entecavir suppress viral replication, while interferon‑alpha induces innate immunity. For HCV, DAAs target nonstructural proteins NS3/4A protease, NS5A replication complex, and NS5B RNA polymerase, achieving sustained virologic response rates >95% across genotypes. No approved antiviral exists for HAV; prevention relies on vaccination and hygiene measures.

Mechanism of Action

Hepatitis A

HAV lacks a therapeutic target; treatment is supportive. The vaccine induces neutralizing antibodies against the viral capsid, preventing viral entry into hepatocytes by blocking receptor binding.

Hepatitis B

Reverse‑transcriptase inhibitors (e.g., entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide) competitively inhibit the HBV polymerase’s reverse‑transcriptase domain, preventing synthesis of the negative‑sense DNA strand from the pregenomic RNA template. This blockade halts viral replication and reduces covalently closed circular DNA (cccDNA) pools. Pegylated interferon‑alpha exerts antiviral effects by upregulating interferon‑stimulated genes, enhancing innate immune responses, and inducing apoptosis of infected hepatocytes.

Hepatitis C

DAAs are subdivided into three mechanistic classes:

• NS5B polymerase inhibitors (e.g., sofosbuvir) are nucleotide analogues that incorporate into the viral RNA chain, causing chain termination.

• NS5A inhibitors (e.g., ledipasvir, daclatasvir) disrupt the replication complex by binding to the NS5A protein, preventing RNA synthesis and virion assembly.

• NS3/4A protease inhibitors (e.g., simeprevir, paritaprevir) block the viral protease required for processing the polyprotein into functional nonstructural proteins.

Combination therapy targeting multiple steps achieves synergistic inhibition, reduces resistance emergence, and yields high sustained virologic response (SVR) rates.

Clinical Pharmacology

Pharmacokinetics

Pharmacodynamics

Therapeutic Applications

• Hepatitis A: No antiviral therapy; vaccination recommended for travelers, MSM, and individuals with chronic liver disease.

• Hepatitis B: Entecavir 0.5 mg daily; Tenofovir alafenamide 25 mg daily; Peginterferon alfa‑2a 180 µg weekly for up to 48 weeks. Indicated for chronic HBV with high viral load, elevated ALT, or advanced fibrosis.

• Hepatitis C: Sofosbuvir + ledipasvir 400 mg/90 mg daily for 12 weeks (genotype 1, 4, 5, 6). Sofosbuvir + daclatasvir 400 mg/60 mg daily for 12 weeks (genotype 3). Sofosbuvir + ribavirin for genotype 4, 5, 6 or treatment‑naïve patients with cirrhosis. Peginterferon + ribavirin for select genotype 1 patients with contraindications to DAAs.

• Off‑label uses: Tenofovir disoproxil fumarate for HIV co‑infection; Ledipasvir in combination with sofosbuvir for HCV genotype 1b in patients with cirrhosis.

• Special populations: Pediatric: Entecavir 0.1 mg/kg daily; Tenofovir alafenamide 5 mg daily. Geriatric: dose adjustments rarely needed; monitor renal function. Renal/hepatic impairment: Tenofovir alafenamide preferred in renal dysfunction due to lower plasma tenofovir levels. Pregnancy: Entecavir and tenofovir are category B; ribavirin is contraindicated.

Adverse Effects and Safety

Common side effects include fatigue, headache, nausea, and mild elevations in transaminases. Serious adverse events vary by agent:

• Entecavir: Rare cases of lactic acidosis; monitor for myopathy in patients on statins.

• Tenofovir alafenamide: Lower risk of renal toxicity than tenofovir disoproxil fumarate; monitor eGFR and serum phosphate.

• Sofosbuvir: Generally well tolerated; consider caution in severe renal impairment (eGFR <30 mL/min).

• Ledipasvir: Pruritus, rash; rare cases of anemia.

• Peginterferon alfa‑2a: Flu‑like symptoms, depression, cytopenias, thyroid dysfunction.

• Ribavirin: Dose‑dependent hemolytic anemia; contraindicated in pregnancy.

Major drug interactions are summarized below:

Monitoring parameters include baseline and periodic liver function tests, renal function, complete blood count, and viral load. Contraindications are active severe liver disease (Child‑Pugh C), uncontrolled psychiatric illness for interferon, and pregnancy for ribavirin.

Clinical Pearls for Practice

• Always confirm HBsAg positivity before initiating nucleos(t)ide therapy; monitor HBeAg seroconversion as a marker of response.

• Use tenofovir alafenamide over disoproxil fumarate in patients with baseline eGFR <60 mL/min to minimize nephrotoxicity.

• For HCV genotype 3, add ribavirin to the sofosbuvir + daclatasvir regimen to achieve SVR >95% in cirrhotic patients.

• In pregnancy, prefer tenofovir alafenamide or entecavir; avoid ribavirin and interferon.

• Vaccinate all patients with chronic liver disease against HAV to prevent fulminant hepatic failure.

• Use the mnemonic “BRAIN” (Baseline, Renal, Age, Indication, Neutropenia) to decide on peginterferon therapy.

• When treating HCV in patients with renal impairment, consider sofosbuvir‑based regimens only if eGFR >30 mL/min; otherwise, use a sofosbuvir‑free DAA combination.

Comparison Table

Exam‑Focused Review

Common question stems revolve around antiviral selection, resistance patterns, and safety in special populations. Students often confuse the mechanism of tenofovir disoproxil fumarate versus tenofovir alafenamide, or the role of ribavirin in HCV therapy.

• Question stem: A 45‑year‑old man with chronic HBV and eGFR 45 mL/min is started on therapy. Which agent is most appropriate?

• Answer: Tenofovir alafenamide, due to lower renal toxicity.

• Question stem: A 60‑year‑old woman with HCV genotype 3 and compensated cirrhosis requires treatment. Which regimen yields the highest SVR?

• Answer: Sofosbuvir + daclatasvir + ribavirin for 12 weeks.

• Question stem: A patient develops severe fatigue and flu‑like symptoms after starting peginterferon. What is the most likely cause?

• Answer: Interferon‑induced flu‑like syndrome; consider dose adjustment or switch to DAA.

Key differentiators include:

• Tenofovir alafenamide has a lower systemic tenofovir exposure compared to disoproxil fumarate.

• Ribavirin is the only DAA class with significant hemolytic anemia.

• Peginterferon requires monitoring for thyroid dysfunction; DAAs do not.

Key Takeaways

1. HAV is managed solely by vaccination; no antiviral therapy exists.

2. HBV treatment hinges on nucleos(t)ide analogues; tenofovir alafenamide is preferred in renal impairment.

3. HCV DAAs target NS5B, NS5A, and NS3/4A; combination therapy yields >95% SVR.

4. Monitor renal function when prescribing tenofovir disoproxil fumarate; switch to alafenamide if eGFR <60 mL/min.

5. Ribavirin is contraindicated in pregnancy due to teratogenicity.

6. Vaccination against HAV is essential for all patients with chronic liver disease.

7. Use the mnemonic BRAIN to assess peginterferon candidacy.

8. Always verify HBsAg and HBeAg status before initiating HBV therapy.

9. In HCV genotype 3 cirrhosis, add ribavirin to achieve optimal SVR.

10. Screen for depression before starting peginterferon; monitor thyroid function during therapy.

Always integrate evidence‑based guidelines with individual patient factors; multidisciplinary collaboration ensures optimal outcomes for hepatitis patients.